$3.795
-0.105[-2.69%]
Last update: 11:00AM Get Real Time Here
Aquestive Therapeutics
(NASDAQ:AQST)Aquestive Therapeutics Stock (NASDAQ:AQST), Analyst Ratings, Price Targets, Predictions
Aquestive Therapeutics Inc has a consensus price target of $8.56, established from looking at the 26 latest analyst ratings. The last 3 analyst ratings were released from Piper Sandler, HC Wainwright & Co., and Raymond James on April 11, 2024, April 5, 2024, and March 28, 2024. With an average price target of $8.67 between Piper Sandler, HC Wainwright & Co., and Raymond James, there's an implied 128.37% upside for Aquestive Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Piper Sandler
HC Wainwright & Co.
Raymond James
JMP Securities
Wedbush
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Aquestive Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/11/2024 | AQST | Buy Now | Aquestive Therapeutics | $3.79 | 163.5% | Piper Sandler | David Amsellem | → $10 | Initiates | → Overweight | Get Alert |
| 04/05/2024 | AQST | Buy Now | Aquestive Therapeutics | $3.79 | 137.15% | HC Wainwright & Co. | Raghuram Selvaraju | → $9 | Reiterates | Buy → Buy | Get Alert |
| 03/28/2024 | AQST | Buy Now | Aquestive Therapeutics | $3.79 | 84.45% | Raymond James | Gary Nachman | → $7 | Initiates | → Outperform | Get Alert |
| 03/18/2024 | AQST | Buy Now | Aquestive Therapeutics | $3.79 | 137.15% | HC Wainwright & Co. | Raghuram Selvaraju | $7 → $9 | Maintains | Buy | Get Alert |
| 03/15/2024 | AQST | Buy Now | Aquestive Therapeutics | $3.79 | 163.5% | JMP Securities | Jason Butler | $8 → $10 | Maintains | Outperform | Get Alert |
| 03/11/2024 | AQST | Buy Now | Aquestive Therapeutics | $3.79 | 84.45% | HC Wainwright & Co. | Raghuram Selvaraju | $6 → $7 | Maintains | Buy | Get Alert |
| 03/07/2024 | AQST | Buy Now | Aquestive Therapeutics | $3.79 | 137.15% | Wedbush | Andreas Argyrides | $4 → $9 | Maintains | Outperform | Get Alert |
| 03/07/2024 | AQST | Buy Now | Aquestive Therapeutics | $3.79 | 110.8% | Lake Street | Thomas Flaten | $3 → $8 | Maintains | Buy | Get Alert |
| 11/08/2023 | AQST | Buy Now | Aquestive Therapeutics | $3.79 | 58.1% | HC Wainwright & Co. | Raghuram Selvaraju | $5 → $6 | Maintains | Buy | Get Alert |
| 10/10/2023 | AQST | Buy Now | Aquestive Therapeutics | $3.79 | 5.4% | Wedbush | Andreas Argyrides | → $4 | Reiterates | Outperform → Outperform | Get Alert |
| 10/10/2023 | AQST | Buy Now | Aquestive Therapeutics | $3.79 | 31.75% | HC Wainwright & Co. | Raghuram Selvaraju | → $5 | Reiterates | Buy → Buy | Get Alert |
| 09/22/2023 | AQST | Buy Now | Aquestive Therapeutics | $3.79 | 5.4% | Wedbush | Andreas Argyrides | → $4 | Reiterates | Outperform → Outperform | Get Alert |
| 09/22/2023 | AQST | Buy Now | Aquestive Therapeutics | $3.79 | 31.75% | HC Wainwright & Co. | Raghuram Selvaraju | → $5 | Reiterates | Buy → Buy | Get Alert |
| 09/21/2023 | AQST | Buy Now | Aquestive Therapeutics | $3.79 | 110.8% | JMP Securities | Jason Butler | → $8 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 07/31/2023 | AQST | Buy Now | Aquestive Therapeutics | $3.79 | 31.75% | HC Wainwright & Co. | Raghuram Selvaraju | → $5 | Reiterates | Buy → Buy | Get Alert |
| 06/30/2023 | AQST | Buy Now | Aquestive Therapeutics | $3.79 | 110.8% | JMP Securities | Jason Butler | → $8 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 06/21/2023 | AQST | Buy Now | Aquestive Therapeutics | $3.79 | 31.75% | HC Wainwright & Co. | Raghuram Selvaraju | → $5 | Reiterates | Buy → Buy | Get Alert |
| 06/05/2023 | AQST | Buy Now | Aquestive Therapeutics | $3.79 | 31.75% | HC Wainwright & Co. | Raghuram Selvaraju | → $5 | Reiterates | Buy → Buy | Get Alert |
| 03/09/2023 | AQST | Buy Now | Aquestive Therapeutics | $3.79 | 5.4% | Wedbush | Andreas Argyrides | $3 → $4 | Upgrade | Neutral → Outperform | Get Alert |
FAQ
What is the target price for Aquestive Therapeutics (AQST)?
The latest price target for Aquestive Therapeutics (NASDAQ: AQST) was reported by Piper Sandler on April 11, 2024. The analyst firm set a price target for $10.00 expecting AQST to rise to within 12 months (a possible 163.50% upside). 18 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Aquestive Therapeutics (AQST)?
The latest analyst rating for Aquestive Therapeutics (NASDAQ: AQST) was provided by Piper Sandler, and Aquestive Therapeutics initiated their overweight rating.
When was the last upgrade for Aquestive Therapeutics (AQST)?
The last upgrade for Aquestive Therapeutics Inc happened on March 9, 2023 when Wedbush raised their price target to $4. Wedbush previously had a neutral for Aquestive Therapeutics Inc.
When was the last downgrade for Aquestive Therapeutics (AQST)?
There is no last downgrade for Aquestive Therapeutics.
When is the next analyst rating going to be posted or updated for Aquestive Therapeutics (AQST)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aquestive Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aquestive Therapeutics was filed on April 11, 2024 so you should expect the next rating to be made available sometime around April 11, 2025.
Is the Analyst Rating Aquestive Therapeutics (AQST) correct?
While ratings are subjective and will change, the latest Aquestive Therapeutics (AQST) rating was a initiated with a price target of $0.00 to $10.00. The current price Aquestive Therapeutics (AQST) is trading at is $3.80, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.